T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.

Although all three BsAbs could delay tumor growth, BC275 appeared to extend survival of the mice more, although the difference between BC275 and BC269 did not reach statistical significance ( figure 5 ).

also in 111,027 other papers